Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 616,887 shares, a growth of 11,142.7% from the August 15th total of 5,487 shares. Based on an average daily volume of 893,115 shares, the days-to-cover ratio is presently 0.7 days. Currently, 5.5% of the company’s stock are sold short.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Wedbush decreased their price target on shares of Aprea Therapeutics to $3.00 and set an “outperform” rating for the company in a research report on Thursday, August 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Aprea Therapeutics currently has a consensus rating of “Hold” and an average price target of $3.07.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. AIGH Capital Management LLC raised its stake in shares of Aprea Therapeutics by 174.1% during the first quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock valued at $775,000 after purchasing an additional 645,000 shares in the last quarter. DRW Securities LLC bought a new position in Aprea Therapeutics in the 4th quarter valued at about $103,000. Finally, Jane Street Group LLC bought a new stake in shares of Aprea Therapeutics during the 4th quarter worth about $40,000. Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Stock Down 1.9%

Shares of NASDAQ:APRE opened at $0.77 on Friday. The company has a market cap of $9.75 million, a PE ratio of -0.72 and a beta of 1.54. Aprea Therapeutics has a fifty-two week low of $0.55 and a fifty-two week high of $1.69. The firm has a 50-day simple moving average of $0.72 and a 200 day simple moving average of $0.78.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.11. Aprea Therapeutics had a negative return on equity of 47.60% and a negative net margin of 4,405.59%. As a group, research analysts forecast that Aprea Therapeutics will post -0.34 EPS for the current fiscal year.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.